Daily 1-alpha-OH-D2 in Hormone Refractory Prostate Cancer: Assessment of Clinical and Biochemical Effects
Abstract
The goals of this proposal were to examine the clinical effectiveness of vitamin D analog therapy (l-alpha hydroxyvitamin D2 in patients with advanced androgen-independent prostate cancer. We performed a phase II study of l-alpha hydroxyvitamin D2 administered daily at doses from 12.5 to 5.0 ug/day and examined various laboratory correlative studies for any correlation with outcome. Daily administration of l-alpha hydroxyvitamin D2 was well tolerated with occasional grade 1 and rare grade 2 hypercalcemia. No objective tumor responses were observed but 6 out of 20 evaluable patients had stable disease for greater than or less than 6 months. Treatment with 1-alpha hydroxyvitamin D2 was associated with decreased serum PTH levels and increased urine calcium levels. Plasma TGF-beta-1 levels and T cell receptor zeta chain analysis in peripheral T cells did not correlate with clinical outcome as related to vitamin D-based therapy. These findings support further study of the potential clinical effectiveness of vitamin D-based therapies in advanced prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2001
- Accession Number
- ADA393144
Entities
People
- Howard H. Bailey
Organizations
- University of Wisconsin–Madison